219 related articles for article (PubMed ID: 19233641)
1. Oncogenic gene fusions in epithelial carcinomas.
Prensner JR; Chinnaiyan AM
Curr Opin Genet Dev; 2009 Feb; 19(1):82-91. PubMed ID: 19233641
[TBL] [Abstract][Full Text] [Related]
2. Morphologic features of carcinomas with recurrent gene fusions.
Qi M; Li Y; Liu J; Yang X; Wang L; Zhou Z; Han B
Adv Anat Pathol; 2012 Nov; 19(6):417-24. PubMed ID: 23060067
[TBL] [Abstract][Full Text] [Related]
3. Commonality but diversity in cancer gene fusions.
Rabbitts TH
Cell; 2009 May; 137(3):391-5. PubMed ID: 19410533
[TBL] [Abstract][Full Text] [Related]
4. Evidence of recurrent gene fusions in common epithelial tumors.
Kumar-Sinha C; Tomlins SA; Chinnaiyan AM
Trends Mol Med; 2006 Nov; 12(11):529-36. PubMed ID: 17011825
[TBL] [Abstract][Full Text] [Related]
5. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
Shah RB; Chinnaiyan AM
Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
[TBL] [Abstract][Full Text] [Related]
6. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
7. [Chromosomal rearrangements and fusion genes in carcinoma].
Massard C; Auger N; Lacroix L; Bénard J
Bull Cancer; 2011 Dec; 98(12):1395-401. PubMed ID: 22172776
[TBL] [Abstract][Full Text] [Related]
8. Landscape of gene fusions in epithelial cancers: seq and ye shall find.
Kumar-Sinha C; Kalyana-Sundaram S; Chinnaiyan AM
Genome Med; 2015 Dec; 7():129. PubMed ID: 26684754
[TBL] [Abstract][Full Text] [Related]
9. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.
Veeraraghavan J; Ma J; Hu Y; Wang XS
Breast Cancer Res Treat; 2016 Jul; 158(2):219-32. PubMed ID: 27372070
[TBL] [Abstract][Full Text] [Related]
10. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
[TBL] [Abstract][Full Text] [Related]
11. Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.
Loo SK; Yates ME; Yang S; Oesterreich S; Lee AV; Wang XS
Genes Chromosomes Cancer; 2022 May; 61(5):261-273. PubMed ID: 35106856
[TBL] [Abstract][Full Text] [Related]
12. Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes.
Celestino R; Sigstad E; Løvf M; Thomassen GO; Grøholt KK; Jørgensen LH; Berner A; Castro P; Lothe RA; Bjøro T; Sobrinho-Simões M; Soares P; Skotheim RI
Genes Chromosomes Cancer; 2012 Dec; 51(12):1154-64. PubMed ID: 22961909
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
14. Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer.
Kalyana-Sundaram S; Shankar S; Deroo S; Iyer MK; Palanisamy N; Chinnaiyan AM; Kumar-Sinha C
Neoplasia; 2012 Aug; 14(8):702-8. PubMed ID: 22952423
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal aberrations in solid tumors.
Chinnaiyan AM; Palanisamy N
Prog Mol Biol Transl Sci; 2010; 95():55-94. PubMed ID: 21075329
[TBL] [Abstract][Full Text] [Related]
16. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
17. Recurrent gene fusions in prostate cancer.
Kumar-Sinha C; Tomlins SA; Chinnaiyan AM
Nat Rev Cancer; 2008 Jul; 8(7):497-511. PubMed ID: 18563191
[TBL] [Abstract][Full Text] [Related]
18. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
19. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
